Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

PHASE2UnknownINTERVENTIONAL
Timeline

Start Date

October 31, 1999

Conditions
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
BIOLOGICAL

filgrastim

DRUG

docetaxel

DRUG

gemcitabine hydrochloride

Trial Locations (12)

20010

Washington Cancer Institute, Washington D.C.

21204

St. Joseph Medical Center, Towson

22031

Northern Virginia Oncology Group, Fairfax

33486

Center for Hematology-Oncology, Boca Raton

38119

Memphis Cancer Center, Inc., Memphis

49201

Hematology & Oncology Associates of Southern Michigan, Jackson

60031

Oncology-Hematology Associates of North Illinois, Ltd., Gurnee

76012

Arlington Cancer Center, Arlington

92093

University of California San Diego, La Jolla

95819

Sacramento Center for Hematology and Medical Oncology, Sacramento

04074

Maine Center for Cancer Medicine and Blood Disorders, Scarborough

13217-6962

Hematology Oncology Associates of Central New York, Syracuse

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY